About the BO17708 study
BO17708 is an international phase III trial which randomized 736
patients who did not receive previous chemotherapy for their metastatic
breast cancer to one of three groups;
-- Avastin 7.5 mg/kg every 3 weeks in combination with docetaxel
-- Avastin 15 mg/kg every 3 weeks in combination with docetaxel
-- docetaxel + placebo as control arm
The primary objective of the study was to demonstrate superiority in progression-free survival of both Avastin containing treatment arms compared to the control arm. Secondary endpoints for the study included overall survival, response rate, duration of response, quality of life, safety and tolerability.
Data from the comprehensive Avastin cancer clinical development
programme have resulted in approvals in advanced colorectal, breast, lung,
and kidney cancer:
-- February 2004 (US) and January 2005 (EU) -- first-line treatment in
patients with metastatic colorectal cancer (CRC).
-- June 2006 (US) -- second-line treatment in patients with metastatic
-- October 2006 (US) -- first-line treatment in patients with advanced
non-small cell lung cancer (NSCLC).
-- March 2007 (EU) -- first-line treatment in patients with metastatic
-- April 2007 (Japan) -- treatment in patients with recurrent or advanced
-- August 2007 (EU) -- first-line treatment in patients with advanced
-- December 2007 (EU) -- first-line treatment in patients with advanced
-- January 2008 (EU) -- first and later-line treatment in patients with
metastatic CRC in combination with any chemotherapy.
All trademarks used or mentioned in this release are legally protected.
To access video clips about Avastin, in broadcast standard, free of
charge, please go
Copyright©2008 PR Newswire.
All rights reserved